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Purpose: The purpose was to determine if maximal muscle performance varies across the 
menstrual cycle because historically this measurement has been left out of research and women 
report feeling differences between phases. Strength and ballistic force production were measured 
in normally cycling eumenorrheic women and in women on hormonal birth control. We expected 
greater performance during the follicular vs. luteal phase because of fluctuating hormones, 
specifically estrogen, for the normally cycling women and more constant values for women on 
birth control because of the lack of fluctuating hormones due to effects of birth control. 
Methods: Participants were physically active women between 18-40 years who were 
either 1) eumenorrheic and not taking hormonal birth control (N=13), or 2) taking birth control 
(N=10). Ovulation was determined via body temperature and LH strips, and along with menses, 
was tracked for one full cycle prior to strength testing as well as during their two months of 
strength testing. Identical assessments were performed on four visits in the luteal and follicular 
phases over two consecutive months of menstrual cycles. Tests included leg and arm strength, 
ballistic force production, and vertical jump.  
Results: Comparisons were made between the luteal and follicular phases within subjects 
and between the normally cycling and hormonal birth control groups. No significant differences 
were found in for strength or ballistic functional measures between menstrual phases or between 
the groups (p=>0.05). 
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Conclusions: Meaningful differences between phases would suggest that hormonal 
fluctuations affect muscle performance. We found no difference in muscle function between 
follicular and luteal phases. This suggests that the hormonal variation during the menstrual cycle 
is insufficient to alter maximal neuromuscular output. One possibility is that the relatively low 
number of participants hampered the ability to detect differences. If there are no differences 
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Considering the recent federal movement (Mazure & Jones, 2015) for the equal inclusion 
of females and males in research studies,  a clearer understanding is needed of the potential 
influence of menstrual phases on various aspects of physiological function. Historically, studies 
have often excluded women out of convenience and therefore some important clinical findings 
do not account for responses in women (Mazure & Jones, 2015). In the case of disease diagnosis 
and treatment, this practice could be detrimental to the health of women. 
A more complete understanding in this area should aid in the interpretation of sex-based 
differences in future studies. For example, in the context of neuromuscular performance 
outcomes such as muscle strength (Mazure & Jones, 2015), knowledge of the impact of 
menstrual cycle on the expression of strength would enable designers of research studies to time 
data collection appropriately.    
Furthermore, in the strength and conditioning realm, application of evidence-based 
training programs to female athletes based on results from men could be less effective due to sex 
differences in endocrine responses underlying muscle adaptation and physiological mechanisms 
that benefit athletic performance (Chilibeck, Calder, Sale, & Webber, 1998). A more complete 
understanding of how fluctuations in female sex hormones affect performance would allow 
athletes and coaches to use this knowledge to optimize training programs.  
Numerous studies have shown that women exhibit greater muscle strength during the 
follicular phase of the menstrual cycle compared with the luteal phase (Hudgens, 1988; Sarwar, 
1996; Sung, 2014; Mohamed, 2000; Phillips, 1996; Chilibeck, Calder, Sale, & Webber, 1998) . 
This trend has been observed in a variety of muscles using a variety testing protocols; however, 
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the physiological mechanisms that underlie the differences across menstrual phases are not 
completely understood. Strength output involves a contribution from both the nervous system 
activation and muscle contractile function (Mohamed & Abdel-Rahman, 2000). Likewise, 
menstrual cycle-based differences in strength have been attributed to the acute effects of 
increased estrogen on both muscle contraction (Mohamed, 2000) and neuromuscular activation 
(McEwen, 1999). Estrogen has been found to be excitatory to the central nervous system (CNS) 
(Mohamed & Abdel-Rahman, 2000) and trophic to muscle (McEwen & Alves, 1999), in contrast 
to progesterone, which can inhibit nervous system function in part to the influence on GABA 
(gamma-Aminobutyric acid is the main inhibitory neurotransmitter in the CNS) function in the 
CNS (McEwen & Alves, 1999) and may contribute to muscle dysfunction (McEwen & Alves, 
1999). This is thought to be the primary notion underlying the greater strength and performance 
during the follicular phase when estrogen is high and progesterone is low, compared with the 
luteal phase when estrogen is lower, and progesterone is relatively higher.  
That said, the current body of literature on this question is not conclusive, and furthermore is 
lacking an explanation of the mechanism of this effect. Some of the studies that have compared 
strength performance between the two phases show a significant difference (Hudgens, 1988; 
Sarwar, 1996; Sung, 2014; Mohamed, 2000; Phillips, 1996; Chilibeck et al., 1998)  and some do 
not (Slauterbeck, 2002; Janse de Jonge, 2003; Elliott, 2005 Janse de Jonge, 2001). Furthermore, 
there has been no research on menstrual cycle-related differences in explosive, ballistic force 
production, whether in isolated muscle testing or explosive whole-body movements. For many 
athletes, an important underlying feature of performance is their ability to produce muscle force 
rapidly and exert powerful movements (Iguchi et al., 2011).  
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Given the potential influence of hormonal fluctuations on nervous system and muscle 
function, the purpose of this study was to determine if muscle strength and ballistic performance 
vary significantly across the phases of the menstrual cycle. Strength and ballistic force 
production were measured in eumenorrheic women with ostensibly normal hormonal 
fluctuations and in women taking hormonal birth control. The expectation was that performance 
would be greater in the follicular vs. Luteal phase for the normally cycling women and be more 



















1. LITERATURE REVIEW 
It is now somewhat appreciated that human research studies should include both sexes 
when appropriate (Mazure, 2015). Failing to do so generally decreases the quality and 
applicability of information gained, interferes with meaningful interpretation of the efficacy of 
clinical or exercise interventions, and could unintentionally reinforce negative sex-based 
stereotypes and create inequities in health outcomes (Mazure, 2015). More needs to be done to 
clear up conflicting outcomes and address the lack of data surrounding women’s health research 
(Mazure, 2015). 
 
Athletic performance in female athletes 
Recent research is conflicting on how sex hormones may affect the performance of 
female athletes. Overall, the exact mechanism that explains this effect is not entirely understood. 
The purpose of a recent paper by Mcewen et al. was to tackle the complexity of the integration of 
the endocrine system and the nervous system (McEwen, 1999). They did this by exploring how 
fluctuations associated with the menstrual cycle can modify the motor nervous system in vivo 
and how the menstrual cycle could influence motor behavior (McEwen, 1999). 
Sex hormones, and their precursors and metabolites, have been shown to have a profound 
effect on the nervous system. They can be either excitatory or inhibitory to the nervous system. 
For example, pregnenolone, a progesterone precursor, has been shown to increase the inhibitory 
effect of GABA and produce an inhibitory effect on the nervous system (Schultz, 2009). 
In addition, estrogen, specifically estradiol, plays a large role in the maintenance of the 
central nervous system. It appears to play a role in the development and trophism of the nervous 
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system and has a net excitatory/trophic effect. Recent work in rodents has indicated that estrogen 
receptors on GABA releasing (GABAergic) neurons may be the primary way in which estradiol 
creates a net excitatory effect on the nervous system Schultz, 2009). Activation of estrogen 
receptor α on GABAergic neurons attenuates the release of GABA. This mechanism explains 
how estradiol rapidly affects neurotransmitter pathways for both dopamine (Becker, 1990) and 
glutamate (Smith, Waterhouse, Chapin, & Woodward, 1987) in rodent models. This excitatory 
effect has been shown in vivo whereby estradiol administration increases neuronal discharge of 
the rat cerebellum during treadmill walking (Smith, Waterhouse, & Woodward, 1988). This 
mechanism explains how estradiol rapidly affects neurotransmitter pathways for dopamine and 
glutamate. This increase in neuronal discharge during treadmill walking has been shown in 
rodent models (Smith, 1988).   
 The role of estrogen has been studied using different methods. First, via direct 
nervous system stimulation techniques, and second, by recording single motor unit activity 
during voluntary contractions. Early research has shown that the amplitude of H-reflexes elicited 
by stimulation of the peripheral nerve does not change during the menstrual cycle, however the 
corticospinal tract excitability is highest and inhibition lowest in the late follicular phase 
compared to early follicular or mid-luteal (Smith, 1988).  Altogether, the stimulation research 
suggests that the function of the descending motor tracts is altered during the menstrual cycle 
and may be facilitated in the late follicular phase. 
 Neurological function related to sex hormones was tested by using a hand 
steadiness assessment between men and women. They did this in two different experiments 
including 58 men, 19 women taking hormonal birth control, and 48 normally cycling women, 
ages 18-32 years. In the first study they were tested for their ability to hold a stylus in a series of 
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holes without touching the hole. They found the normally cycling women were steadier than the 
men in the follicular phase, but the women on hormonal birth control had significantly less hand 
steadiness overall. The normally cycling women, however, showed significant performance 
changes associated with cycle phases,   performing the best in the follicular phase and worse in 
the luteal phase. All subjects performed better with their dominant hand. For the second part of 
the experiment, five women taking oral contraceptives and seven normally cycling women were 
tested with dummy pistols weighted to simulate medium and large caliber revolvers. Each 
weighted handgun was tested in a supported and unsupported testing position. The normally 
cycling women made fewer aiming errors compared with the women on oral contraceptives. 
However, the performance of the normally cycling women was significantly impaired during the 
week prior to menses. The steadiness advantage of the normally cycling women was similar for 
the different pistol weights (Hudgens, Fatkin, Billingsley, & Mazurczak, 1988).  
Sports medicine professionals typically describe two functionally different units of the 
vastus medialis (VM) and the vastus medialis oblique (VMO), despite there being no differences 
anatomically. Griffin et al. sought to determine if the motor units of the VM and VMO are 
recruited differently due to sex hormones and the different phases of the menstrual cycle (Tenan, 
Peng, Hackney, & Griffin, 2013). They measured single motor unit recordings from each muscle 
in men and women from the isometric knee extension measurement. They measured 11 men at 
one time point and seven women were tested at five different time points during the menstrual 
cycle. They found that the initial firing of the VMO compared to the VM fluctuated in women 
but not in men. They found that in women, initial firing rate in the VM was higher in the early 
follicular to late luteal phase and the VMO was lower in initial firing rate than the VM during 
ovulation and midluteal phases. They concluded that the control of the VM and VMO change 
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across the menstrual cycle and could contribute to the greater incidence of knee injuries in 
women compared to men (Tenan et al., 2013) 
Relating psychological factors and perception of effort to performance might better 
explain the differences found throughout the menstrual cycle (Simic, Tokic, & Pericic, 2010). 
For example, Simic et al. assessed the effects of the menstrual cycle on motor and spatial tasks, 
anxiety, and perceived exertion. They tested 20 participants, ages 18 to 21 years, with a regular 
menstrual cycle. The participants performed a finger dexterity test and mental rotation test during 
menstruation, late follicular, and the midluteal phase. Before each test, they were given the 
anxiety questionnaire and rate of perceived exertion was measured via the Borg scale. The 
results showed the best performance in both tests in the midluteal phase, when both estrogen and 
progesterone are relatively elevated. The anxiety level and task difficulty ranking were the 
highest in the early follicular phase, when the hormone levels were the lowest (Simic et al., 
2010). 
 
Effect of estrogen on skeletal muscle 
Less is understood about the acute effects of estrogen on muscle function compared with 
the chronic effects. For example, estrogen is known to provide a chronic protective and trophic 
effect on skeletal muscle (Prochniewicz et al., 2008). After menopause, women experience a 
decline in skeletal muscle mass which has been linked to the dramatic post-menopausal decrease 
in estrogen levels (Prochniewicz et al., 2008). Recently, electron paramagnetic resonance (EPR) 
spectroscopy was used to directly investigate the trophic effects of estradiol on myosin in 
muscles of female mice. They discovered several acute effects of removing estrogen in these 
mice. The implications of the findings were three-fold. First, after the removal of estrogen they 
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found a reduced function in myosin along with a reduction of specific force (force per unit 
mass). They then returned estrogen levels to normal with estrogen treatments and the reductions 
were reversed. They found the reduction was due to structural changes in the myosin head 
specifically (Wattanapermpool, Riabroy, & Preawnim, 2000). Second, they concluded that 
estrogen is a very important hormone that affects force generation at a molecular level. Last, 
myosin was specifically identified as a contractile protein detrimentally affected by reduced 
estradiol levels (Moran, 2007).   
 
Strength during the menstrual cycle 
Healthy eumenorrheic women who are not taking hormonal birth control should have 
fluctuating highs and lows of progesterone and estrogen during the menstrual cycle. The relevant 
question here is how this affects performance outcomes such as maximal force. One study 
examined muscle strength and the rate of fatigue between phases of the menstrual cycle in 100 
healthy women ages 18-24 years (Pallavi, UJ, & Shivaprakash, 2017). Strength and fatigue rate 
were assessed using a handgrip dynamometer. They found that handgrip strength was 20% 
higher in the follicular phase (higher estrogen and low progesterone) compared with the luteal 
phase (lower estrogen and high progesterone) (Pallavi, 2017). 
 In contrast, Dr. Janse de Jonge, a prominent researcher in this area, has found that 
strength and endurance performance are not affected by female sex hormones. Her research 
suggests that oxygen consumption, heart rate, and responses to submaximal steady state exercise 
are not affected by the menstrual cycle and that women do not need to adjust their training or 
competition schedule around their cycle phases (Janse de Jonge, 2003). Dr. de Jonge’s group 
tested the influence of the different phases of the menstrual cycle specifically on the contractile 
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characteristics of skeletal muscle. They looked at both phases and measured maximal isometric 
quadriceps strength and fatiguability, electrically stimulated contractile properties of the knee 
extensors, and handgrip strength. They found no significant differences between the two phases 
of the cycle and concluded that the cycle-related fluctuations in sex hormones do not affect 
muscle contractile characteristics.  
In contrast, one of the first studies on strength and menstrual cycle assessed differences in 
muscle strength between the luteal and follicular phases and compared women on hormonal birth 
control to women not taking birth control. The eumenorrheic group (N = 10) exhibited 11% 
greater handgrip and quadriceps strength in the follicular compared with the luteal phase. The 
hormonal birth control group (N=10) was used as a control group and they were found to have 
no differences in strength across the menstrual cycle compared to the eumenorrheic group 
(Sarwar, Niclos, & Rutherford, 1996).  
 Muscle strength of the adductor pollicis (AP) was studied throughout the menstrual cycle 
to determine whether any variation in force is associated with the known cyclical changes in 
ovarian hormones (Phillips, Sanderson, Birch, Bruce, & Woledge, 1996). Three groups of young 
women were studied: regularly menstruating trained (N=10), and untrained (N=12) and trained 
hormonal birth control users (N=5). They had one control group of untrained men (n =10). The 
trained women were competition rowers. They measured maximum voluntary force (MVF) of 
AP which measured over a period of 6 months. The trained women were measured three times a 
week before practice and the untrained women tested eight different times to still get the same 
amount of testing done but since they don’t have practice, they mimicked the amount and time of 
testing as the training group. Ovulation was detected by luteinizing hormone measurements or 
change in basal body temperature. Their results showed a significant 10% increase in MVF 
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during the early follicular phase of the menstrual cycle when estrogen levels are rising, in both 
the trained and untrained groups. This was followed by a similar drop in MVF around the time of 
ovulation when estrogen is at its peak. Neither the hormonal birth control group nor the male 
subjects showed cyclical changes in MVF (Phillips, 1996). 
In this area of investigation many researchers have focused on the female menstrual cycle 
in relation to strength. The concern for some investigators is related to fluctuating hormone 
levels, strength, and joint ligament laxity as a contributor to greater ligament injury rates. One 
study sought to test if the ACL define injuries occur randomly or were more prevalent during 
specific phases of the menstrual cycle (Slauterbeck et al., 2002) Researchers asked athletes to 
complete a post-knee injury questionnaire that determined the timing of their last menstrual cycle 
and if they were on birth control or not. Each subject provided a saliva sample to determine their 
progesterone and estrogen levels at the time of the questionnaire to determine the timing of their 
cycle relative to the time of injury. They did this to correlate actual hormone levels with the self-
report of menses at the time of injury. Ten out of 27 athletes sustained an ACL injury 
immediately before or one to two days after their menses. They determined that the increase in 
injury rate on days one and two of the menstrual cycle was greater than random chance 
(Slauterbeck, 2002). 
It is important not only to understand what a single strength test or maximal output looks 
like between phases, but to also understand on a daily, monthly, and yearly basis how hormones 
affect training, competition, and practice. One study examined hormone fluctuations in the 
menstrual cycle and how it affects strength training and muscle building during strength training 
workouts (Sung et al., 2014). The women in this intervention study were placed into two groups. 
one group performed eight sessions of leg press training during their luteal phase and two 
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sessions during their follicular phase, and the other group performed the opposite pattern of 
training between phases. The researchers found that the participants who did most of their leg 
press sessions in the follicular phase increased type 1 and type 2 muscle fiber size. They also 
increased their maximum isometric force from single fibers (f-max), and the single fiber 
diameter as measured by real time ultrasound imaging and had alterations in  estrogen and 
progesterone; both progesterone and estrogen levels overall decreased at the end of the 
intervention. In contrast, the other group, who did the majority of their leg press sessions in the 
luteal phase, experienced no alterations muscle fiber type, size, hormone levels, f-max, or fiber 
diameter from pre- to post-test. They demonstrated that follicular phase-based strength training 
induces significantly greater effects on strength and muscle and that a periodized program based 
around their menstrual cycle would be beneficial for performance (Sung, 2014). 
 
Hormonal Birth Control and Exercise 
Despite the minimal research on women taking hormonal birth control, it is generally 
understood that for women on birth control, performance and hormone changes are far different 
compared with women not on birth control (Elliott et al., 2005). Women on hormonal birth 
control do not have the same hormonal fluctuations as a eumenorrheic woman and therefore do 
not have a normal menstrual cycle including ovulation and menses (Elliott, 2005). Hormonal 
birth control is typically administered in three different forms (monophasic, biphasic or triphasic) 
that differ widely in how they affect the body (Elliott et al., 2005). Therefore, the outcomes of 
performance measures for women on hormonal birth control might be expected to vary. Since 
fluctuations in sex steroids are believed to be a possible factor in performance and exercise 
capacity, it is important to understand the effect of administering various types of hormonal birth 
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control to women. However, the research into oral contraceptives and exercise performance is 
not consistent. 
The type of hormonal birth control administered (monophasic, biphasic or triphasic), as 
well as the type and dose of estrogen and progesterone may have varying effects on exercise 
performance (Elliott, 2005). To date, research in the area of oral contraceptives and exercise 
capacity is sparse and muddled by poor research design, methodology and small sample size 
(Elliott, 2005). It is clear from the research to date that more information is needed on the array 
of types of birth control in women’s health generally and specifically on exercise performance 
(Elliott, 2005). 
One such study examined the effects of oral contraceptive use on maximal force 
production in young women (Burrows, 2007).  They studied two groups with a total of 21 female 
participants (14 on hormonal birth control and seven eumenorrheic controls). All participants 
taking birth control had been taking a combined, monophasic oral contraceptive pill for at least 
six months. Maximum dynamic and isometric leg strength, maximum isometric strength of the 
first dorsal interosseus (FDI) muscle, and plasma concentrations of estrogen and progesterone 
were measured on days seven and 14 of pill consumption and day five of pill withdrawal. The 
eumenorrheic group was tested on days two and 21 of the menstrual cycle. They concluded that 
there were no significant changes in muscle strength between test day two (follicular phase) and 
21 (the luteal phase) for either of the groups. They also found the hormonal birth control group 
did not significantly differ from the eumenorrheic group, even though the eumenorrheic group 
had significant fluctuations in estrogen and progesterone throughout their menstrual cycle 
compared with the lack of fluctuations with the hormonal birth control group. Altogether, 
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hormonal birth control users were similar compared with eumenorrheic women not taking 
hormonal birth control on measures of muscle strength (Burrows, 2007). 
Although the effects of exogenous estrogen and progesterone on muscle strength has not 
been completely determined there have been mechanisms suggested through which hormonal 
birth control may enhance athletic performance, 1) increasing growth hormone levels in response 
to exercise, thereby attenuating delayed-onset muscle soreness, and 2) reducing the incidence of 
injuries by reducing fatigue caused by premenstrual syndrome (Nichols, 2008).  Previous studies 
suggest that the use of monophasic, combination hormonal birth control does not significantly 
affect peak torque or isometric strength (Nichols, 2008). For example, Nicholas et al. found that 
the use of combination hormonal birth control has no effect on maximal force production 
measured by adductor pollicis longus maximum voluntary contraction, knee extension/flexion 
peak torque, and forearm isometric endurance (Nichols, 2008). This study was designed to 
investigate the effects of combination birth control on strength in collegiate softball and water 
polo female athletes. The athletes participated in a 12-week strength development program. A 
double-blind research design was used to mask subjects to the main outcome of interest, strength 
gain differences between groups. The researchers were blinded to the hormonal birth control use 
of participants until data collection was completed.  They studied two groups including 13 birth 
control users and 18 eumenorrheic women not taking any form of birth control. All subjects 
participated in the same supervised 12-week pre-season strength development program. Their 
strength tests at weeks 0 (pre-test), 4, 8, and 12 (post-test) included one-repetition maximum 
bench press (1RMBP), 10-repetition maximum knee extension (10RMLE), isokinetic peak 
torque bench press (IKBP), and isokinetic peak torque knee extension (IPKE). They found a 
significant increase in strength over the course of the 12-week study which was found 
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consistently between both groups for all tests. No significant differences in IKBP torque 
production occurred during the 12-week strength training program. No significant differences pre 
and post-test over the 12-week strength training program in 1RMBP, 10RMLE, IKBP, or IKLE 
occurred between the birth control group and non-birth control group. They concluded that the 
use of combination birth control did not provide an androgenic effect sufficient to increase 
strength gains more than the stimulus from the training protocol (Nichols, 2008). 
  
Ballistic muscle performance across the menstrual cycle 
Maximal muscle force (muscle strength), considered above, is an important and well-
characterized feature of muscle function (Aagaard, 2002). It is also important to consider the 
speed of muscle contraction, or rate of force development (RFD) (Aagaard, 2002). However, to 
our knowledge no studies have examined this functionally important outcome with regard to the 
female menstrual cycle. What is known is that in vivo estrogen has an excitatory effect on the 
central nervous system and that progesterone has an inhibitory effect (Smith et al., 1987), which 
suggests a possible impact on explosiveness as measured by the rate of force development. One 
study tested and validated the methods necessary to measure and analyze RFD and efferent 
neuromuscular drive of human skeletal muscle after heavy resistance strength training. This 
training induced gain in explosive muscle strength could be explained by increases in efferent 
neural drive, as evidenced by marked elevations in EMG signal in the early phase of muscle 
contraction (Aagaard, 2002). Altogether, the notion that estrogen has an excitatory effect on the 






Overall, in the current literature, the results and outcomes are conflicting. First, research 
does show in mouse models and in vivo, that there are hormonal effects of estrogen and 
progesterone at the cellular level in skeletal muscle and in the nervous system. However not all 
research consistently reflects that at the level of functional or performance outcomes. There are a 
few studies that display differences between phases of the menstrual cycle, and there are those 
that failed to find differences. There are inconsistencies in the way that researchers have 
measured hormone levels and ovulation, which may be part of the reason for inconsistency of 
results on menstrual phase and muscle strength. Rate of force development is typically used as a 
measure of power output and athletic performance but has never been measured in respect to the 
phases of the menstrual cycle. Theoretically, there could be differences due to the neurological 
effects of estrogen and progesterone. 
 It is also clear that the production of sex hormones from reproductive organs may only 
account for a small change in the level of hormones in the nervous system (Mazure & Jones, 
2015). Moreover, the amount of sex hormones in nervous tissue is not uniformly distributed, and 
it is unknown how menstrual cycle irregularities and hormonal contraception affect the nervous 
system. With that, it is possible that sex hormones may substantially increase or decrease human 
performance but is difficult and complicated to capture the effects in athletic performance or 
rehabilitation gains in humans. The intra-individual variability is complex, and it is difficult to 
control other contributing factors such as training level, specific sport, nutrition, sleep, mental 
focus and their interaction with nervous system function. The effect of hormonal variations on 







Female participants between 18-40 years of age were recruited via word of mouth and 
advertisements posted in local exercise facilities. They provided written informed consent after 
screening and orientation to the procedures. The experimental protocol was approved by the 
Human Research Committee at Colorado State University. 
During the initial phone screening and in the subsequent questionnaire, subjects reported 
regular participation, moderate to vigorous levels of physical activity that specifically includes 
regular strength training. This was defined as a minimum of two strength training sessions per 
week on a consistent basis for at least a year. Each participant reported their strength training to 
be 4-6 days per week on average at a moderate to high intensity. All women in the eumenorrheic 
(EUM) group reported normal menstrual cycles for at least one year and had not taken hormonal 
birth control for at least six months prior to the study. One of the eumenorrheic participants was 
using a non-hormonal IUD. The hormonal birth control group has been on birth control for at 
least six months. Five of the participants were on monophasic birth control, two were on biphasic 
and three were using hormonal IUD’s. Participants in both groups reported no major health 
problems, nor neurological or muscle disease.  
 
3.2  Menstrual Cycle Tracking 
For each subject, participation and testing schedules were staggered according to the 
timing of entry into the study. Participation in the study took place over the course of three 
consecutive months. After entry into the study and prior to testing, on the first visit each 
 17 
 
participant had a DEXA scan to determine bodyfat % and lean body mass. They were also given 
instructions for tracking their specific start date, end date and details of menstruation and their 
ovulation for one month. No strength assessments were performed during this first month (the 
tracking month). The EUM group tracked the start and duration of their menstrual cycle and the 
timing of ovulation with daily oral temperature readings and luteinizing hormone (LH) strips 
(Proven™) that were provided (Guida et al., 1999). Each participant was provided instructions 
on the use of the LH strips in the days surrounding ovulation and how to properly obtain their 
basal body temperature each morning immediately upon waking. According to manufacturer’s 
instructions, the strips were dipped in urine for 5 s and laid flat for up to 10 minutes to read the 
ovulation results. Using both daily temperature readings and the LH strip data (Guida et al., 
1999), the Ovia fertility tracking app (Ovia Health) was employed to determine the timing of the 
beginning and end of the follicular and luteal phases.  
 After the tracking month, four identical experimental sessions were carried out in the 
second and third months. During this eight-week testing period they continued to use the app to 
track their cycle using body temperature but did not use the LH strips. For the EUM group, one 
session was performed in the mid follicular and mid luteal phases in each of the two testing 
months. For the HBC the testing sessions were timed similarly in the absence of information 
about menstrual phase. Each HBC participant has a time point indicated with their birth control 
regimen when their period should be. Based on that timing, testing was scheduled on a cycle like 
the EUM group with testing approximately (2-3-day window) every two weeks.    
 
3.3 Procedures 
3.3.1 Knee Extension Device  
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A custom testing chair was used for measurement of strength and rate of force 
development (RFD).  Subjects were seated in an upright position with the hip at a 90 degree 
angle. The pelvis and thighs were firmly secured with straps to prevent movement of adjacent 
body segments and maintain joint position. Knee extension force was measured perpendicular to 
the shank with a load cell positioned above the ankle. Force measurements were digitized at 250 
Hz (1401 A/D device, Cambridge Electronic Design, UK) and stored on computer using Spike2 
software (Spike 2, version 7.14., Cambridge Electronic Design, UK.)  
 
3.2.2    Isometric strength and rate of force development 
Rate of force development (RFD) and maximal voluntary contraction (MVC) force was 
measured from force data recorded from each leg separately during explosive bilateral maximal 
knee extension tasks. For a trial, participants were instructed to increase the knee extension force 
as rapidly as possible in both legs simultaneously and then exert a maximal voluntary force for 2-
3 seconds (Aagaard, Simonsen, Andersen, Magnusson, & Dyhre-Poulsen, 2002). Strong verbal 
encouragement was provided for the ballistic start of the trial and during the maximal force 
portion. The maximal forces were recorded for both legs from each trial during the one min 
between-trial rest periods. At least three trials were performed with a goal of two maximal force 
values within 5% of each other for each leg. Additional trials were performed up to a maximum 
of five trials. The 5% criteria was met for all subjects within five trials (Aagaard et al., 2002).   
 
3.2.3    Vertical jump assessment 
The purpose of this test was to measure functional lower limb explosive performance by 
measuring vertical jump height (Vertec Vertical Jump Trainer, Sport Imports). To set the 
baseline height of the device, the subject stood upright and reached vertically as far as possible 
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with the arms together and the fingers extended (Rodriguez-Rosell, Mora-Custodio, Franco-
Marquez, Yanez-Garcia, & Gonzalez-Badillo, 2017). The vertical distance from the floor to the 
tips of the fingers represented the baseline position of the device. Stance width was measured 
from the preferred jump stance and replicated within-subject for consistency across subsequent 
tests (Rodriguez-Rosell et al., 2017).  An iPod Touch (5th generation) was firmly attached the 
lateral aspect of the left thigh with Velcro straps to measure the rotation rate of the thigh during 
the upward propulsion phase of each jump. The face of the iPod Touch was oriented in the 
sagittal plane.  
No pre-propulsion counter movement was allowed. The 90-degree starting knee angle 
was measured initially with a manual goniometer and then replicated thereafter using an 
adjustable horizontal rod suspended between two supports. The foot position on the floor was 
always a known and consistent distance from the rod. Immediately prior to each jump the subject 
re-assumed the foot stance width and slowly squatted so that the proximal posterior thigh 
touched the rod. This positioning and procedure ensured that a consistent starting knee angle was 
established. No swinging of the arms was allowed (Rodriguez-Rosell et al., 2017). While 
keeping the hands together out stretched above their head, the participants were instructed to 
jump vertically, complete the upward phase with their arms outstretched straight up, and attempt 
to touch and move the highest possible indicator on the device. With instruction, three practice 
jumps were performed at a participant-estimated 25%, 50%, and 75% of maximum (Rodriguez-
Rosell et al., 2017). Then, three maximal effort jumps were performed where the subject 
attempted to move the highest slider possible on the device. At least 30s of rest was provided 
between each maximal attempt. Care was used to replicate positioning and technique across all 




3.2.4    Peak rotation 
In addition to the vertical jump height, the rotation rate of the thigh segment was 
measured using the gyroscope signal from the iPod Touch. The gyroscope measures the tilt of 
the device in the pitch axis which provides information about the transverse axis rotation (sagittal 
plane movement) of the thigh during the upward propulsion phase of each jump attempt. A data 
collection application (Sensor Data, Wavefront Labs) was used to sample the gyroscope sensor 
data at 100 samples/s. The application also calculated the rate of rotation around the pitch axis. 
The data were downloaded to computer and imported into the Spike 2 program for analysis 
(Cambridge Electronic Design, UK.).   
 
3.2.5  1-RM Leg press  
The purpose of this task was to determine the maximum inertial load the subjects could 
lift with a bilateral hip and knee extension. A recumbent leg press machine (Magnum Fitness 
Systems) was used. The feet were placed in a consistently replicated location on a fixed 
platform. The leg press action moved the seat backward along polished rails with low-friction 
bearings. The seat was adjusted, and the feet placed such that the goniometer-measured starting 
knee angle for the press movement was 100 degrees.  Each attempt involved relatively slow 
(non-ballistic) simultaneous knee and hip extension until the legs were straight. Identification of 
the 1-RM load involved single lift attempts that began at a moderate load estimated to be 
approximately 50% of maximum and increased progressively up to maximum, with at least one-
minute rest between trials. Subjects were blinded as to not see what weight they were doing or be 
able to compare it to the next time. They were provided strong and consistent verbal 
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encouragement during each attempt. When a load was attempted that could not be lifted through 
the specified ROM, the last successfully lifted load was recorded as the 1-RM load. Intermediate 
1kg weights were used to apply more precise loads between each weight plate if necessary. 
Subjects required 5-8 trials to determine the 1-RM load. Subjects were not allowed to grip the 
handrails during the testing. 
 
3.2.6    Elbow flexion device 
The purpose of this task was to assess maximal voluntary force production for the elbow 
flexor muscles (Tracy, Dinenno, Jorgensen, & Welsh, 2008). A custom testing chair with a rigid 
platform for elbow flexion force measurement was used for measurement of maximal voluntary 
isometric force and rate of force development (RFD). Subjects were seated in an upright position 
with the torso and left shoulder strapped firmly to the chair. The shoulder was slightly abducted 
and the elbow at a 100-degree angle. The semi-prone forearm was placed in a form-fitting 
adjustable plastic orthosis that was fixed to the load cell with the axis of measurement 
perpendicular to the forearm/orthosis at the position of the wrist. Force measurements were 
digitized at 250 Hz (1401 A/D device, Cambridge Electronic Design, UK) and stored on 
computer using Spike2 software (Spike 2, version 7.14., Cambridge Electronic Design, UK.) 
(Tracy et al., 2008).  
 
3.2.7    Isometric strength and rate of force development 
The MVC and RFD measures were obtained using the same procedures and analysis as 
with the knee extensors. The elbow flexion task was only performed on the left arm due to 




3.2.7 Data analysis and reduction  
The MVC tasks were performed bilaterally and values were recorded from each leg 
separately. The MVC force and RFD values were measured on each leg from the trial with the 
greatest maximal force value. The length of the lever arm was measured along the lower leg 
from the center of rotation of the knee joint to the point of application of force into the load cell 
so the knee extension torque could be expressed. The RFD was quantified as the amount of force 
(% of maximum torque) generated during specified time periods; 30, 50, 100, and 200 
milliseconds. The MVC force was simply the maximal force value from the maximal trial in that 
session. The MVC values from the left and right legs were summed to produce an overall 
bilateral MVC value as the KE isometric strength dependent outcome.  
For the RFD calculation, the onset of the increase in force was determined using the 
upper bounds of the noise in the force signal in the 2 seconds prior to the visually evident rise in 
force (14). A horizontal cursor was placed at the upper bound of the noise and the 0-s timepoint 
was where this cursor intersected the rising force. This manual, upper-bound, conservative 
method was chosen in order to ensure that the onset was clearly defined after the rise in force 
began and was not defined too early due to fluctuations in the baseline force before the task 
began (Aagaard et al., 2002). The RFD values were obtained by placing cursors at 30, 50, 100, 
and 200ms after the onset of the increase in force. The slope of the torque increase (% maximum 
torque/s) was measured for the 0-30, 0-50, 0-100, 0-200ms periods (Aagaard et al., 2002). 
The MVC and RFD was analyzed similarly for the knee extensor and elbow flexor task. 
No lever arm values were measured for the elbow flexors; thus, the strength and RFD values 
were expressed in units of force (N) and percent of maximum force. 
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The vertical jump (cm) was calculated as the difference between the baseline position of 
the device and the highest slider that was moved during the maximum jump attempts. 
For the iPod Touch-measured movement speed of the thigh, the peak rotation rate (0.1s 
window) around the pitch axis was measured from the upward propulsion phase of each maximal 
jump attempt. The maximal peak rotation rate (rad/s) from all attempts was taken as the 
dependent outcome for this measure.   
 
3.4 Statistical analysis 
Analysis of variance with repeated measures (RMANOVA) was used. The between-subject 
factor was group; eumenorrheic (EUM) or hormonal birth control (HBC). The within-subjects 
factors were menstrual phase (follicular or luteal) and month (month one, month two). 
Differences between menstrual phases (main effect of menstrual phase) and differences between 
groups for the effect of menstrual phase were examined via the menstrual phase x group 
interaction. Within-subjects contrasts (a priori) were examined based on the expectations 





















4.1 Subject Characteristics 
 
Thirteen women in the eumenorrheic group (28.2 ± 6 years) and 10 women in the 
hormonal birth control (26 years ± 4 years) completed testing. The two groups were similar (P > 
0.05) for age (27.2 years ± 5 years), height (165.3 cm ± 8.6 cm), body mass (66.5 kg ± 12.2 kg ), 
BMI (24.1 kg/m2 ± 3 kg/m2) lean body mass (46.3 kg ± 6.9 kg), and body fat percentage (27.6% 
± 5.1).  
Table 1. 
  Group  Mean Std. Deviation 
Age Eumenorrheic 28.2 6.2 
 
HBC 26.2 3.9 
BMI Eumenorrheic 23.5 2.7 
  HBC 24.7 2.8 
Weight 
(kg) 
Eumenorrheic 63.9 8.6 
  HBC 69.1 15.8 
Height 
(cm) 
Eumenorrheic 164.2 6.3 
 
HBC 166.4 10.8 
LBM 
(kg) 
Eumenorrheic 44.9 4.7 
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  HBC 48.0 9.0 
BF % Eumenorrheic 27.3 4.6 
  HBC 27.9 5.5 
 
4.2 Knee extensor isometric strength 
Right vs. left leg. The MVC force for the left leg was significantly less than the right 
mean (831 ± 194 vs. 891 ± 231 N, P > 0.05). There was no group x leg interaction, therefore the 
right and left leg values were summed to produce a bilateral MVC force value as the main 
dependent outcome for knee extensor isometric strength. All MVC results for the knee extensors 
are summed across legs. 
 
Month one vs. month two. Bilateral MVC was reduced by 6% in month two compared 
with month one (1755 ± 93 vs.1669 ± 82 N, main effect of month P = 0.02). There were no 
differences in this effect between groups (group x month interaction P = 0.93) or between 
follicular and luteal phases (month x phase interaction P = 0.47). 
 
Eumenorrheic vs. Hormonal birth control group. Bilateral MVC was not different 
between groups (1739 ± 117 vs. 1685 ± 128 N, main effect of Group P = 0.73). There were no 




Follicular vs. Luteal phases. Bilateral summed KE MVC was found to be similar 
between follicular and luteal phases (1723 ± 83 vs. 1701 ± 95 N, main effect of month P = 0.37). 
There were no differences in the phase effect between months (phase x month interaction P = 
0.47). Bilateral summed KE MVC was not different between follicular and luteal phases for 
either the EUM group (1744 ± 111 vs. 1735 ± 127 N) or the HBC group (1702 ± 121 vs. 1668 ± 
140 N, group x phase interaction P = 0.73). 
 
4.3 Elbow flexor isometric strength 
Month one vs. month two. Elbow flexion was reduced in testing month two compared 
with month one (228 ± 10 vs. 215 ± 10 N, main effect of Month P = 0.01).  There was also a 
difference in this effect between groups such that month two showed higher isometric strength 
values compared to the first month (group x month interaction P = .013) but no difference 




Eumenorrheic vs. hormonal birth control group. Elbow flexor MVC was not different 
between groups (216 ± 13 vs. 227 ± 14 N, main effect of group P = 0.84).  
Follicular vs. luteal phases. Elbow flexion MVC was not different between the follicular 
and luteal phases (229 N ±10 N vs. 215 N ± 10 N, main effect of menstrual phase P = 0.39).  
Elbow Flexion MVC was not different between follicular and luteal phases for the eumenorrheic 
group (222 N ± 14 N vs. 210 N ± 13 N), and hormonal birth control group (235 N ± 15 N vs. 220 
N ± 15 N, main effect of group by phase P = 0.84). 
 
4.4 Leg press dynamic strength 
Month one vs. month two. Leg press strength was reduced by 0.8% between month one 
and month two (130 ± 5 vs. 129 ± 4 Kg, main effect of month P = 0.01).  There was no 
difference in this effect between groups (group x month interaction P = 0.89) or between 
follicular and luteal phases (month x phase interaction P = 0.83). 
 
Eumenorrheic vs. birth control group. Leg press strength was not different between 
groups (126 ± 6 vs. 132 ± 7 Kg, main effect of group P = 0.89). 
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Follicular vs. luteal phases. Leg press strength was not significantly different between 
the follicular and luteal phases (130 ± 5 vs. 127 ± 4 Kg, main effect of phase P = 0.07). The two 
groups were not significantly different, the eumenorrheic group (127 ± 6 vs. 124 ± 6 Kg) 
compared with the hormonal birth control group (135 ± 7 vs. 130 ± 6 Kg), main effect of group x 
phase P = 0.61). 
 
4.5 Vertical jump height 
Month one vs. month two. Jump height was the same between month one and month two 
(31.9 ± 1.3 vs. 31.7 ± 1.2 cm, main effect of month P = 0.71).  There were no differences in this 
effect between groups (group x month interaction P = 0.23) or between follicular and luteal 
phases (month x phase interaction P = 0.64). 
 
Eumenorrheic vs. hormonal birth control group. Jump height was the same between 
groups (32.7 ± 1.5 vs. 30.9 ± 1.7 cm, main effect of group P = 0.23).  
 
Follicular vs. luteal phases. Jump height was not significantly different between the 
follicular and luteal phases (32.0 ± 1.3 vs. 31.6 ± 1.1 cm, main effect of phase P = 0.55). The 
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difference between phases was not different between the EUM group (32.9 ± 1.7 vs. 32.4 ± 1.5 
cm), and HBC group (31.1 ± 2 vs. 30.7 ± 1.7 cm, main effect of group x phase P = 0.97). 
  
4.6 Peak rotation rate 
Month one vs. month two. Peak rotation rate was not different between month one and 
month two (6.97 ± 0.2 vs. 6.94 ± 0.2 rad/s, main effect of month P = 0.9).  There were no 
differences in this effect between groups (group x month interaction P = 0.5) or between 
follicular and luteal phases (month x phase interaction P = 0.4). 
 
Eumenorrheic vs. hormonal birth control group. Peak rotation rate was the same between 
groups (6.8 ± 0.298 vs. 7 ± 0.319 rad/s) between follicular and luteal phases (group x phase 
interaction P = 0.39). 
 
Follicular vs. luteal phases. Peak rotation rate was not significantly different between the 
follicular and luteal phase (6.9 ± 0.20 vs. 7.0 ± 0.26 rad/s, main effect of phase P = 0.31). The 
difference between phases was not different between the eumenorrheic group (6.7 ± 0.27 vs. 6.8 
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± 0.36 rad/s), and hormonal birth control group (7.0 ± 0.29 vs. 7.3 ± 0.38 rad/s), main effect of 
group x phase P = 0.55). 
 
 
     4.7 Rate of Force Development 
4.7.1 Knee Extensors 
For the 30, 50, 100, and 200ms time periods, the RFD (%MVC/s) for the elbow flexor 
muscles was not significantly different between month one and month two, between groups, or 
between phases (month, group, and phase main effect P > 0.05; Figure 6). Furthermore, the EUM 
and HBC groups exhibited a similar lack of difference between phases (group x phase interaction 




4.7.2 Elbow Flexors 
For the 30, 50, 100, and 200ms time periods, the RFD (%MVC/s) for the elbow flexor muscles 
was not significantly different between month one and month two, between groups, or between 
phases (month, group, and phase main effect P > 0.05; Figure 7). Furthermore, the EUM and 









The overall objective of the current study was to determine if muscle performance varied 
between different phases of the menstrual cycle. Outcomes were compared between the follicular 
and luteal phase and included strength and ballistic force production of the knee extensors and 
the elbow flexors, vertical jump height, and thigh rotation rate. The strength of both elbow 
flexors and knee extensors was not different between phases of the menstrual cycle for the 
eumenorrheic and birth control groups. The vertical jump, an explosive, functional multi-joint 
muscle performance measurement, also did not vary across the menstrual cycle or between 
groups. For both leg and arm muscles, the rate of force increases in the earliest phases of 
contraction (30, 50,100, 200 ms) was not different between the follicular and luteal phases for 
either group. Overall, the data suggest no systematic difference in muscle performance between 
phases of the menstrual cycle. 
The most classic study to examine strength during the menstrual cycle reported a 
significant difference in quadriceps and hand grip strength between the follicular and luteal 
phases. In the eumenorrheic group both quadriceps and handgrip strength were 11% greater in 
the follicular compared with luteal phase (Sarwar et al., 1996). They also tested women who 
were taking hormonal birth control and found that muscle function remained constant across the 
cycle. They concluded that since women on birth control have a more constant estrogen level, 
they didn’t experience the same changes in muscle function at mid-cycle like the normally 
cycling women do, who exhibit an increase of estrogen in the follicular phase before ovulation. 
Similarly, we studied strength output in two consecutive cycles in the mid-late follicular phase 
(day 8 on average) and the mid luteal phase (day 18 on average) this needs defined sooner. 
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Sarwar et al determined the menstrual cycle days by counting day one of menses and counting 
until day 14 assuming that was the ovulation day. We specifically measured ovulation for each 
participant, determining their ovulation day within 1-2 days. Each participant tracked their cycle 
with an app, used LH strips, and measured basal body temperature to determine more precisely 
when they ovulated.  
One study also found an increase in strength in the follicular phase. They measured 
maximum voluntary force (MVF) of the adductor pollicis which was measured over a maximum 
period of six months (Phillips et al., 1996). Like our study, they tracked ovulation using 
luteinizing hormone measurements and change in basal body temperature. There was a 
significant increase in MVF (about 10%) during the follicular phase of the menstrual cycle in 
both the trained and untrained groups. They also found there to be a drop in MVF shortly after 
ovulation (Hudgens et al., 1988). Similar, Tenan et al. found that in the in the follicular phase 
women activate their VMO more than in their luteal phase, also as compared to men, and women 
on birth control, who saw no differences (Tenan et al., 2013). 
De Jonge et al. examined the influence of the different phases of the menstrual cycle on 
skeletal muscle contractile characteristics and found no differences between phases (Janse de 
Jonge, 2003). They tested 19 regularly menstruating women. Muscle function was measured 
when estrogen and progesterone concentrations were low (menstruation), when estrogen was 
elevated at its peak (ovulation) and when progesterone was low (late follicular phase), and 
estrogen and progesterone were both elevated (early luteal phase). Maximal isometric quadriceps 
strength, hand grip strength, fatiguability and electrically stimulated contractile properties were 
measured along with isokinetic knee flexion and extension strength and fatiguability. They were 
much more precise with their hormone measurements than our study and determined the 
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menstrual cycle phases through measurement of estrogen, progesterone, follicle stimulating 
hormone and luteinizing hormone from blood samples. As with our findings, they found that 
there were no significant changes in any of the parameters between any of the phases they tested. 
They did not test women on birth control and do not have an explanation or comparison of the 
effects that birth control might have on muscle contractility.  They concluded that these results 
suggest the fluctuations in female sex hormones during the menstrual cycle do not influence 
muscle contractility.  
One reason to strive to understand the effects of the menstrual cycle on performance is if, 
and how, training programs and competition schedules should be structured around the menstrual 
cycle. Should women plan their training around their cycle to maximize gains in performance? 
There are several studies that compare training effects between phases. One study compared the 
effects of strength training in the follicular phase compared with the luteal phase (Sung et al., 
2014). One group trained more leg press sessions during the follicular phase and the other group 
performed more sessions during the luteal phases. They used self-report and a menses-based 
prediction method to determine ovulation and cycle phases. They found that women who trained 
more in the follicular phase had a greater increase in strength output after the training period 
compared with the women who trained more in the luteal phase. Although this study is not 
directly comparable to our findings, it does at least provide a suggestion that training efficacy 
could be dependent on the timing of the menstrual cycle. 
Other neurological studies have found differences when testing steadiness that were 
tested via hand gun steadiness during shooting tasks. They found that women in the follicular 
phase have greater hand steadiness than during the luteal phase and more so than women on birth 
control in general (Hudgens et al., 1988) . The differences in these studies compared to our 
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findings is an example of the conflicting nature of the literature in this area. Aside from direct 
daily blood hormone measurements, there is also not one single method consistently used to 
determine the exact timing of cycle phases and presumed hormonal fluctuations. If there was one 
consistent measure used by all researchers to determine cycle timing and hormone levels, there 
might be more consistent findings. 
        
Most of the parameters tested in studies of the menstrual cycle involve strength and 
muscle contractility, and performance measures including effects from core temperature changes, 
aerobic capacity, rating of perceived exertion, and fatiguability. To our knowledge, there have 
been no measures of the rate of force development in isolated muscle group testing such as we 
employed. The evaluation of rate of force development during rapid contractions has been 
employed to characterize the explosive strength of athletes, older adults, and clinical patients 
(Aagaard et al., 2002), however there is no information that we are aware of on the effect of 
menstrual cycle phase on rapid force development.  
Interestingly, the present results indicate no systematic difference between the phases in 
strength outcomes or for rate of force development. With this being an important factor 
regarding athletic performance, knowing that rate of force production doesn’t change during the 
menstrual cycle is new valuable information for all athletes and especially power focused 
athletes. Physiologically it has been shown, in vivo, that there is an excitatory neurological effect 
from estrogen (Mazure & Jones, 2015), however, it is possible that effect is not strong enough to 
produce a change in performance, specifically the rate of force development. The rate of force 
development is considered to be related primarily to the discharge rate of motor neurons 
(Aagaard et al., 2002), therefore whatever trophic or potentiating effects that cycle-related 
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fluctuations in sex hormones might exert on neurons, they were not sufficient to alter maximal 
voluntary motor output in our study sample.   
Many of the other studies in this area had a similar sample size to the present study, 
mostly ranging between 12-30 (Hudgens, 1988; Sarwar, 1996; Sung, 2014; Mohamed, 2000; 
Phillips, 1996; Chilibeck et al., 1998) with one study at 100 participants (Pallavi et al., 2017). 
Pallavi et al found that strength increases in the follicular phase of the menstrual cycle by 10%. 
They measured strength via hand grip strength across three phases of the menstrual cycle; 
menses, mid follicular and mid luteal phase early Seeing that they did find a significant 
difference it is possible that most studies, including ours, have too few participants to detect 
differences. This could also explain the inconsistency in findings in this area because too few 
women are being studied in each study to generate statistical power enough to detect differences 
should they exist. If a hormonal effect is the underlying phenomenon it might be of small 
magnitude and therefore difficult to detect with so few participants. Also gathering more data for 
each participant across several menstrual cycles, as opposed to just one or two cycles, could 
provide more within-subject data and produce better understanding how these outcomes may 
fluctuate over time.  
Each participant in our study was experienced with strength training at a reasonably high 
intensity and consistency compared to other studies that have employed a more random sample 
size including trained and untrained women. If the pervasive anecdotal reports produce a 
psychological effect, then it could be possible that women who are accustomed to training at a 
high intensity may psychologically be better able to exert maximal efforts during testing 
regardless of how they may perceive they are feeling. This could be a possible explanation for 




5.1 Study Limitations 
There were a few limitations with our study. First, we did not measure hormone levels 
throughout the cycle via blood work, which is the gold standard measure to precisely determine 
hormone levels. We estimated ovulation via LH strips, basal body temperature, and a tracking 
app. Although reliable, this is still not a definitive method of determining the timing of the 
hormonal fluctuations for each woman. Time was also a limiting factor with only one person 
collecting data, so the capacity of the study was dependent on schedules of the administrator and 
the participant schedules. This limited how many participants could feasibly be tested over the 
time available.  We also did not have precise control over other possible confounding factors 
such as how much strength training they participated in during the study and when, nutrition, 
sleep, stress or other factors that can affect performance and hormone levels. They were simply 
instructed to remain as consistent as possible across the two months of testing, to continue their 
regimen as normal, and not to train on testing days.  
 
5.2 Future Directions 
 Future studies should measure more women more extensively over a longer 
period, so that the strength data is as representative as it can be for an individual. Methods of 
cycle tracking need to be standardized in order to make optimal comparisons and more precisely 
pinpoint hormone levels at the time of testing. Less careful tracking in most of the research in 
this area might have contributed to a lack of consensus in results.  
 Although an inconsistent finding, more studies are needed to describe the underlying 
mechanisms that could contribute to putative differences between phases. Further studies could 
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examine and compare strength trained women and untrained sedentary or recreationally active 
women. Also, psychological queries at the time of testing could assess the subjective feeling of 
vigor or performance during testing. The expression of muscle strength begins with a command 
from the brain, thus this could help to quantitatively measure and explain the perception of 
feeling weaker and stronger throughout the cycle.  
If there are not changes or differences between the follicular and luteal phases, then 
women should be able to train consistently without reservation and plan competitions without 
concern that their cycle-related changes in hormone levels will affect their performance. 
Clinically going forward a rigorous system of understanding and tracking the menstrual cycle in 
research studies needs to be established and implemented so that women are better represented 
and included in more research equally to men.  However, if there really are no differences, then 
the need for concern about cycle effects is eliminated and women can be more easily included in 






















Overall, we found that there were no differences in maximal force or explosive muscle 
output between the mid follicular and mid luteal phases of the menstrual cycle. There appears to 
be no differences between the follicular and the luteal phases or differences between physically 
active women who are normally menstruating versus those who are taking hormonal birth 
control. In vivo hormonal variation is suggested to affect muscle function, but this effect is 
perhaps not strong enough to produce a measurable acute change in muscle performance during 
the menstrual cycle despite the hormonal variation. It is possible that the anecdotal reports are 
explained by psychological effects and fluctuations in the perception of effort rather than the 
underlying neuromuscular physiology. It is possible that there may be a detectable effect with 
more participants in a larger study or arguably that the difference would be more likely to be 
seen with frequent measurements across the cycle rather than with a bigger sample size. The 
results of this study contrast with anecdotal reports of feeling stronger or weaker during different 
points of the menstrual cycle and implies that women may not need to change training or 
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